Penumbra, Inc. (NYSE:PEN) Stock Has Consensus Target Price of $367.07 According to Brokerages

Shares of Penumbra, Inc. (NYSE:PEN) have been assigned a consensus recommendation of “Hold” from the seventeen brokerages that are covering the stock, MarketBeat reports. Fourteen investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $367.07.

Several equities research analysts recently commented on PEN shares. Evercore reiterated an “outperform” rating and issued a $320.00 price objective on shares of Penumbra in a report on Monday, July 6th. Zacks Research raised Penumbra from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research note on Friday, July 17th.

Institutional Trading of Penumbra

A number of large investors have recently made changes to their positions in PEN. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Penumbra during the 2nd quarter valued at $25,000. Keating Financial Advisory Services Inc. bought a new position in shares of Penumbra during the 2nd quarter valued at $31,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Penumbra by 48.7% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 116 shares of the company’s stock valued at $37,000 after buying an additional 38 shares during the period. CoreCap Advisors LLC lifted its holdings in shares of Penumbra by 1,066.7% during the 3rd quarter. CoreCap Advisors LLC now owns 140 shares of the company’s stock valued at $45,000 after buying an additional 128 shares during the period. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Penumbra in the 2nd quarter worth $51,000. 88.88% of the stock is currently owned by institutional investors.

Penumbra Stock Down 0.3%

Penumbra stock opened at $320.06 on Friday. The firm has a market cap of $12.61 billion, a price-to-earnings ratio of 83.37, a PEG ratio of 2.21 and a beta of 0.70. The stock has a fifty day simple moving average of $321.37 and a two-hundred day simple moving average of $322.41. Penumbra has a 12 month low of $221.26 and a 12 month high of $362.41. The company has a current ratio of 5.75, a quick ratio of 3.86 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.28). The business had revenue of $390.05 million during the quarter, compared to analysts’ expectations of $389.64 million. Penumbra had a return on equity of 10.50% and a net margin of 10.67%. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.86 EPS. Equities analysts predict that Penumbra will post 4.96 EPS for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc is a medical device company that develops, manufactures and markets products used to treat vascular conditions and other serious medical disorders. The company is best known for its minimally invasive technologies designed to remove blood clots, restore blood flow and support the treatment of neurovascular conditions, including ischemic stroke.

Its product portfolio includes aspiration and thrombectomy systems, embolization devices, access and delivery systems, and other technologies used by physicians in neurointerventional and peripheral vascular procedures.